Debilitating erosive lichenoid interface dermatitis from checkpoint inhibitor therapy.

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• The increasing use of anti-tumor immunotherapy agents, particularly checkpoint inhibitors, has led to a rise in immune-related adverse events.
• These events stem from the prolonged stimulation of the immune system, affecting various organs and systems.
• Cutaneous reactions are among the recognized immune-related adverse events, but their full spectrum is still being elucidated.

Observation:

• This study presents a case of severe, debilitating erosive lichenoid dermatitis.
• The patient experienced a significant cutaneous reaction secondary to checkpoint inhibitor therapy.
• The presentation was characterized by widespread, erosive, and lichenoid lesions.

Findings:

• Checkpoint inhibitor therapy can induce a wide range of cutaneous immune-related adverse events.
• Erosive lichenoid dermatitis represents a severe manifestation of these skin reactions.
• The case underscores the potential for significant morbidity associated with these adverse events.

Implications:

• Oncologists and dermatologists must be vigilant in recognizing and managing diverse cutaneous immune-related adverse events.
• Early diagnosis and intervention are crucial for mitigating the severity and impact of these reactions.
• Further research is needed to fully characterize the spectrum and underlying mechanisms of immune-related adverse events in patients receiving immunotherapy.